AESTHETIC / SKIN

Botulinum Toxin Type A (Botox)

Botox, Dysport, BTX-A, Clostridium botulinum toxin Type A

CAS Number	94763-96-3
Molecular Formula	Protein (150 kDa)
Molecular Weight	150,000 Da (complex)
Category	Aesthetic / Skin
Available Specifications	100 IU vial (powder), 50 IU vial (powder), Pre-diluted (4IU/0.1mL)

1. OVERVIEW

Botulinum toxin Type A is a potent neurotoxin derived from Clostridium botulinum that irreversibly inhibits acetylcholine release at the neuromuscular junction. FDA-approved for cosmetic and therapeutic uses, BTX-A provides lasting reduction in dynamic wrinkles and muscle hyperactivity through selective motor denervation.

2. MECHANISM OF ACTION

Botulinum toxin operates through selective neuromuscular blocking: (1) translocation across presynaptic membrane at motor nerve terminal; (2) proteolytic cleavage of SNARE proteins (SNAP-25) essential for acetylcholine vesicle fusion; (3) irreversible blockade of acetylcholine release; (4) denervation of target muscle causing paralysis; (5) effect onset 3-7 days, maximal at 2 weeks; (6) gradual recovery over 3-4 months as new nerve terminals form.

3. CLINICAL EVIDENCE & RESEARCH

Extensive literature documents cosmetic efficacy and safety. FDA approval for multiple cosmetic and therapeutic indications. Clinical studies show 90%+ efficacy for wrinkle reduction. Evidence supports use in hyperhidrosis, migraine, spasticity, and other conditions. Long safety record with billions of injections administered.

4. THERAPEUTIC BENEFITS

- Dramatic reduction in dynamic wrinkles
- Non-surgical facial rejuvenation
- Treatment of hyperactive muscles
- Prophylactic wrinkle prevention
- Long-lasting results (3-4 months)
- FDA-approved for cosmetic use
- Therapeutic applications (migraine, dystonia, spasticity)
- Improved hyperhidrosis and excessive sweating

5. INDICATIONS

- Periorbital wrinkles (crow's feet)
- Forehead lines and expression wrinkles
- Glabellar (frown) lines
- Perioral lines and smile lines
- Chin dimpling and marionette lines
- Gummy smile correction

- Preventative wrinkle treatment
- Chronic migraine (therapeutic)
- Cervical dystonia
- Blepharospasm
- Hyperhidrosis (excessive sweating)
- Spasticity

6. DOSING & ADMINISTRATION PROTOCOL

Indication	Dose	Route	Frequency	Duration
Crow's feet (lateral orbicularis oculi)	20-25 IU	Intradermal injection	Every 3-4 months	Ongoing
Forehead (frontalis)	15-20 IU	Intradermal injection	Every 3-4 months	Ongoing
Glabella (corrugator/procerus)	20-25 IU	Intradermal injection	Every 3-4 months	Ongoing
Full face cosmetic	60-100 IU total	Intradermal injection	Every 3-4 months	Ongoing
Hyperhidrosis (per axilla)	50-100 IU	Intradermal injection	Every 6-12 months	Ongoing
Chronic migraine (therapeutic)	155 IU total	Intradermal injections (31 sites)	Every 3 months	Ongoing

Reconstitution

Botulinum toxin supplied as lyophilized powder in vials. Reconstitute with sterile, non-bacteriostatic saline per manufacturer specifications. Typical: 100IU vial + 2.5mL saline = 4 IU/0.1mL concentration. Use immediately or store per protocol (typically 24-48 hours maximum).

Administration

Intradermal injection using 30-32 gauge needle. Inject 0.1mL per site (typically 4 IU per injection for cosmetic use). Multiple injections distributed across target muscles. Avoid injecting during menstruation or immunosuppression. Apply ice pre/post to minimize bruising.

Protocol Notes

Results apparent in 3-7 days; maximal effect at 2 weeks. Duration typically 3-4 months; some patients show 4-6 month duration. May combine with dermal fillers for comprehensive facial rejuvenation. Avoid aggressive facial treatments for 24 hours post-injection. Antibody formation (resistance) develops in 5-10% of patients with repeated use.

7. SIDE EFFECTS & SAFETY PROFILE

- Headache (transient, most common)
- Injection site erythema and bruising
- Transient lid ptosis (1-5% incidence)
- Transient diplopia or lid lag
- Eyebrow ptosis (improper placement)
- Asymmetrical facial appearance (rare with experience)
- Forehead heaviness and brow positioning issues
- Rare systemic effects (extreme overdose)

8. CONTRAINDICATIONS & PRECAUTIONS

- Known allergy to botulinum toxin or albumin
- Neuromuscular disorders (myasthenia gravis, ALS)
- Pregnancy and lactation
- Active skin infection at injection site
- Anticoagulation therapy (relative; increased bruising)
- Uncontrolled diabetes
- Severe facial asymmetry or structural deformity
- Unrealistic patient expectations

Drug Interactions

Potential potentiation with aminoglycosides and other neuromuscular blockers. Anticoagulants increase bruising risk. NSAIDs may increase bruising and ecchymosis. Aspirin should be discontinued 1 week prior.

9. STORAGE & HANDLING

Store reconstituted toxin at 2-8°C. Most manufacturers recommend use within 24-48 hours of reconstitution. Some formulations (e.g., Botox Cosmetic) may be used up to 4 hours at room temperature. Original vials stored at 2-8°C until reconstitution. Do not freeze.

10. KEY REFERENCES

1. Carruthers, J., et al. (2003). "Consensus recommendations on the use of botulinum toxin from the International Society of Aesthetic Plastic Surgery." Plastic and Reconstructive Surgery, 114(6), 1S-22S.

2. Dodick, D.W., et al. (2005). "Botulinum toxin for migraine: mechanism of action." Headache, 45(Suppl 1), S99-S105.

3. Diels, J., et al. (2009). "Safety and efficacy of abobotulinumtoxinA in aesthetic medicine." Clinical, Cosmetic and Investigational Dermatology, 2, 85-92.

Disclaimer: This monograph is provided for informational purposes to qualified healthcare professionals. It does not constitute medical advice. Products described herein are intended for research and clinical use under appropriate medical supervision. Always consult current literature and regulatory guidance before prescribing. Not all products may be approved for clinical use in all jurisdictions. Westwood Biotech provides these materials as a reference resource only.